Adamas to Present at Two Upcoming Investor Conferences
William Blair38th Annual Growth Stock Conferenceon Wednesday, June 13, 2018at 1:20 p.m. CDT JMP Securities Life Sciences Conferenceon Wednesday, June 20, 2018at 3:30 p.m. EDT
The presentations will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. Archived versions of the webcasts will be available via replay for 30 days following the presentations.
Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology. The company is focused on the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only
Ashleigh BarretoDirector, Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc.510-450-3567 firstname.lastname@example.org Media: Terri Clevenger Continuum Health Communications203-227-0209 email@example.com
Source: Adamas Pharmaceuticals, Inc.